Psychemedics CORP 8-K filings

Psychemedics Corporation finalized a stock purchase agreement with 3K Limited Partnership, involving the purchase and subsequent repurchase of shares, along with additional funding for working capital.

Psychemedics Corporation will implement a reverse and forward stock split, effectively cashing out small shareholders, and will delist from the Nasdaq to reduce costs and focus on long-term growth.

Psychemedics Corporation held its annual meeting, where stockholders voted on key proposals including the re-election of directors, executive compensation, and a reverse and forward stock split.

Psychemedics Corporation reported a 9% decrease in revenue for the third quarter of 2024, but a significant reduction in net loss compared to the same period last year.

Psychemedics Corporation announced a 15% decrease in revenue for the second quarter of 2024, alongside a net loss of $0.8 million.

Psychemedics Corporation plans to terminate its public company registration and delist from Nasdaq through a reverse and forward stock split, aiming to reduce costs and enhance long-term value.

Psychemedics Corporation has dismissed BDO USA, P.C. as their independent auditor and engaged Whitley Penn LLP, effective June 12, 2024.

Psychemedics Corporation has terminated its lease agreement for a facility in Culver City, California, effective June 30, 2024, and expects to realize cost savings.

Psychemedics Corporation announced a 9% decrease in revenue and increased net loss for the first quarter of 2024 compared to the same period last year.

Psychemedics Corporation announced a 12% decrease in revenue and a widened net loss for 2023, impacted by ongoing economic challenges and labor shortages.

Psychemedics Corporation's Compensation Committee has approved cash bonus plans for the CEO and other executive officers for 2024, based on financial and individual performance.